Evidence map›Paper›PMID 41691562›Full record

ArticlePaediatric drugs2026

Acute Phase Reaction After First Neridronate Infusion in Children with Osteogenesis Imperfecta: An Analysis Based on Questionnaire Data from 65 Patients.

Felicitas Haselwarter, Stefanie Stasek, Kristina Eva Rehberg, Heike Hoyer-Kuhn, Susanna Reincke, Eva Nüsken, Oliver Semler, Mirko Rehberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Felicitas Haselwarter *Department of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Stefanie Stasek *Department of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. stefanie.stasek@uk-koeln.de.ORCID http://orcid.org/0009-0009-0195-9428
Kristina Eva RehbergSana Hospital Hürth, Hürth, Germany.
Heike Hoyer-KuhnDepartment of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Susanna ReinckeDepartment of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Eva NüskenDepartment of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Oliver SemlerDepartment of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Mirko RehbergDepartment of Pediatrics, Children's Hospital, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.

Funding

Deutsche Forschungsgemeinschaft SE2373/1-2
6 · The paper itself

Abstract

backgroundBisphosphonates represent the current standard of care for the pharmacological treatment of pediatric patients with osteogenesis imperfecta (OI). However, data on acute phase reactions (APRs) after first-time administration, especially with neridronate, remain limited.

objectiveThis study evaluates the incidence, characteristics, and severity of APRs following the initial intravenous neridronate infusion in pediatric OI patients.

methodsSixty-five bisphosphonate-naïve children with genetically or clinically confirmed OI received weight-adjusted intravenous neridronate during a brief hospitalization. Parents documented side effects, including fever onset/duration and skeletal pain, using standardized questionnaires.

resultsNeridronate was generally well tolerated. No severe adverse events occurred. Forty percent of patients developed transient fever. Fever typically emerged within 12-24 h and resolved within 1-2 days. New skeletal pain was reported in 40% of patients, with 60% experiencing severe pain. Mean skeletal pain scores decreased below baseline within 4 days post-infusion. Fever duration did not differ significantly between OI types.

conclusionsFever and skeletal pain are common yet self-limiting side effects after first neridronate infusion in children with OI. Adequate pain medication and caregiver education are important to improve treatment adherence and patient comfort during initiation of bisphosphonate therapy.

Indexed as

Acute-Phase ReactionBone Density Conservation AgentsDiphosphonatesOsteogenesis ImperfectaAdolescentChildChild, PreschoolFemaleHumansInfantInfusions, IntravenousMaleSurveys and Questionnaires6-amino-1-hydroxyhexane-1,1-diphosphonateBone Density Conservation AgentsDiphosphonates

Identifiers

PMID41691562
PMCPMC12992442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.